Leqembi Iqlik™ Now Accessible for Alzheimer's Disease Management
In an exciting development, BioArctic AB's partner Eisai has announced the launch of lecanemab-irmb, marketed as Leqembi Iqlik™, which is now available in the U.S. This innovative treatment offers a new maintenance dosing regimen for Alzheimer's disease (AD), specifically targeting patients diagnosed with Mild Cognitive Impairment (MCI) or mild dementia stages, collectively recognized as early AD.
Following an initial 18 months of treatment via intravenous (IV) administration at a dose of 10 mg/kg every two weeks, patients now have the option to switch to a subcutaneous injection of 360 mg weekly using the Leqembi Iqlik autoinjector. This marks a significant step, making Leqembi Iqlik the first anti-amyloid therapy to facilitate at-home injections post-initial therapy.
Expanded Support with Leqembi Companion™ Program
A key component of this launch is the Leqembi Companion™ program, designed to provide comprehensive resources to support patients throughout their treatment journey. The program includes various tools such as assistance with understanding insurance coverage and potential out-of-pocket expenses, guidance for finding financial assistance, and the option for education through Nurse Educators. These professionals offer training, either in-person or virtually, on using the Leqembi Iqlik autoinjector effectively.
In addition, the program features an injection tracking tool and the Leqembi Companion app, guiding both patients and caregivers in navigating treatment milestones as they progress.
Understanding Alzheimer's Disease and the Role of Lecanemab
Alzheimer's disease is a complex, progressive disorder characterized by neurodegeneration, primarily driven by toxic processes in the brain that precede and continue after the development of amyloid plaques. Lecanemab-irmb stands out due to its dual-action approach; it targets both the protofibrils and plaques associated with amyloid beta (A?), providing a novel mechanism to slow neurodegeneration and combat cognitive decline. This treatment is not just about managing symptoms but also focuses on addressing the underlying pathological processes that aggravate the disease.
Prolonged continuation of maintenance treatment following the initial phase is critical. Studies indicate that without ongoing treatment, patients may experience a rapid return of biomarkers and a decline back to placebo rates, underscoring the importance of ongoing management to help maintain cognitive function longer.
Ease of Use and Efficiency of Treatment
The introduction of Leqembi Iqlik simplifies patient care significantly. This subcutaneous option reduces the need for time-consuming visits to infusion centers. Patients and caregivers can administer treatment comfortably at home, thus reducing healthcare costs associated with nurse supervision, medication preparation, and scheduling. This streamlining not only benefits patients currently in care but also provides additional capacity for new patients needing initial treatment.
Innovative Development through Strong Partnerships
Leqembi is the culmination of a successful partnership between BioArctic and Eisai dating back to 2005. BioArctic initially developed the antibody following breakthroughs by Professor Lars Lannfelt, who discovered the Arctic mutation related to Alzheimer's. Eisai is tasked with overseeing clinical development, regulatory filings, and commercialization processes globally, while BioArctic retains rights for commercial activities in the Nordic countries.
With lecanemab already approved in numerous countries, including the U.S. and parts of Europe, the partnership aims for extensive market penetration, bringing this groundbreaking treatment to those in need. Their comfort in handling the unique hurdles of Alzheimer's treatment ensures a promising future for innovative therapies.
About BioArctic AB
BioArctic AB is a progressive biopharmaceutical company based in Sweden, dedicated to pioneering treatments for neurodegenerative diseases. Known for inventing Leqembi® (lecanemab), BioArctic is committed to crafting innovative solutions that mitigate cognitive decline and delay the progression of Alzheimer's disease. Besides Leqembi, the company is also engaged in research and development aimed at Parkinson's disease, ALS, and other neurodegenerative conditions, leveraging its proprietary BrainTransporter™ technology.
With its stocks publicly listed on Nasdaq Stockholm, BioArctic focuses on providing effective treatments that improve patients' quality of life.
Frequently Asked Questions
What is Leqembi Iqlik?
Leqembi Iqlik is a subcutaneous injection of lecanemab-irmb, used for maintaining Alzheimer's disease treatment in patients after initial intravenous therapy.
How does the Leqembi Companion program support patients?
The program offers resources for understanding insurance, financial assistance and training on using the autoinjector for self-administration.
What is the significance of ongoing treatment for Alzheimer's disease?
Continuing treatment helps to slow disease progression and maintain cognitive function, preventing patients from deteriorating quickly after stopping initial therapy.
Where can Leqembi Iqlik be administered?
Leqembi Iqlik can be administered at home, allowing for greater flexibility and convenience compared to traditional infusion methods.
What role does BioArctic play in the commercialization of Leqembi?
BioArctic collaborates with Eisai for the commercial rollout of Leqembi, focusing on regions like the Nordic countries, as well as developing research for other neurological disorders.
